# Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Canonical URL: https://biopharmsignal.com/news/KURA/kura-oncology-reports-darlifarnib-plus-cabozantinib-demonstrates-robust-activity-in-patients-with-clear-cell-renal-cell-carcinoma-previously-treated-with-cabozantinib
Ticker: KURA
Company: Kura Oncology
Source: Kura Oncology
Published: 2026-04-17 10:00 EST
Original Source URL: https://ir.kuraoncology.com
## Summary

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in

## Article Body
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in
## Recent Company News
- 2026-06-03 10:53 EST — [Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy](https://biopharmsignal.com/news/KURA/kura-oncology-highlights-darlifarnib-s-potential-as-a-foundational-combination-platform-for-kras-mutant-cancers-and-outlines-development-strategy) — Source: Kura Oncology
- 2026-06-02 12:32 EST — [Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML](https://biopharmsignal.com/news/KURA/kura-oncology-and-kyowa-kirin-announce-publication-in-blood-of-ziftomenib-plus-venetoclax-azacitidine-combination-in-patients-with-r-r-npm1-m-aml) — Source: Kura Oncology
- 2026-05-26 10:02 EST — [Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors](https://biopharmsignal.com/news/KURA/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors) — Source: Kura Oncology
- 2026-05-19 20:02 EST — [Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/KURA/kura-oncology-to-present-at-td-cowen-7th-annual-oncology-innovation-summit) — Source: Kura Oncology
- 2026-05-12 20:02 EST — [Kura Oncology Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/KURA/kura-oncology-reports-first-quarter-2026-financial-results) — Source: Kura Oncology
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)